- KR₩42tn
- KR₩45tn
- KR₩4tn
Brief: Celltrion, To Buy 100 Billion Won Worth Of Own Shares
Brief: Celltrion Sets Mid-To-Long Term Shareholder Return Target To One-Third Of Net Profit
South Korean chip stocks rally, tracking US AI gains; Temasek report adds support
Brief: Celltrion Q2 Operating Profit Rises 77.3% Y/Y To 430 Billion Won
Brief: Celltrion Inc To Acquire 100 Billion Won Worth Of Own Shares
Brief: Celltrion Q1 Operating. Profit 322 Billion Won, Up 115% Y/Y
Brief: Celltrion To Cancel 100 Billion Won Treasury Shares
Brief: Celltrion Plans Phase 3 Clinical Trials For Keytruda Biosimilar With 220 Patients
Brief: Celltrion To Buy 100 Billion Won Of Own Shares
Brief: Celltrion Announces U.S. Availability Of Avtozma® (Tocilizumab-Anoh) Subcutaneous (SC) Formulation
CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists
Brief: Celltrion Inc U.S. Unit Celltrion Usa Signs Production Contract With Eli Lilly Worth 473 Million USD
Celltrion to invest up to $478 mln to expand US factory in response to tariffs
Brief: Celltrion To Cell 746 Million Won Worth Of Own Shares
Shares of Asian drugmakers drop after Trump threatens tariffs (updated)
South Korean shares set to snap 4-week rally on US tariff woes
Shares of South Korea’s drugmakers drop after Trump unveils tariffs
South Korean shares hit fresh record as chip, pharma stocks rally
Celltrion unit pays $330 million for Eli Lilly production facility, filing shows (updated)